Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer.

Leukemia - 1 Jun 2024

Arends Christopher Maximilian, Kopp Klara, Hablesreiter Raphael, Estrada Natalia, Christen Friederike, Moll Ute Martha, Zeillinger Robert, Schmitt Wolfgang Daniel, Sehouli Jalid, Kulbe Hagen, Fleischmann Maximilian, Ray-Coquard Isabelle, Zeimet Alain, Raspagliesi Francesco, Zamagni Claudio, Vergote Ignace, Lorusso Domenica, Concin Nicole, Bullinger Lars, Braicu Elena Ioana, Damm Frederik

Abstract excerpt

Clonal hematopoiesis (CH) driven by mutations in the DNA damage response (DDR) pathway is frequent in patients with cancer and is associated with a higher risk of therapy-related myeloid neoplasms (t-MNs). Here, we analyzed 423 serial whole blood and plasma samples from 103 patients with relapsed high-grade ovarian cancer receiving carboplatin, poly(ADP-ribose) polymerase inhibitor (PARPi) and heat shock protein...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carboplatin

Share to Clonal Hematopoiesis

Share to DNA Damage

Share to HSP90 Heat-Shock Proteins

Share to Ovarian Neoplasms

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Protein Phosphatase 2C

Source

Open in PubMed Open full text

Identifiers

PMID: 38637689
DOI: 10.1038/s41375-024-02253-3
PMCID: PMC11147769

Genes

DNMT3A
PPM1D
TET2
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer.PMID 38637689Read ↗

Oncologic therapy shapes the fitness landscape of clonal hematopoiesisSemantic proximity Read ↗

Distinct landscape and clinical implications of therapy-related clonal hematopoiesis.Semantic proximity Read ↗

Monitoring clone dynamics and reversibility in clonal haematopoiesis and myelodysplastic neoplasm associated with PARP inhibitor therapy—a role for early monitoring and interventionSemantic proximity Read ↗

Comprehensive baseline ctDNA characterization in two biomarker-selected Phase 1/2 studies using genomic and methylation profilingSemantic proximity Read ↗

Cancer therapy shapes the fitness landscape of clonal hematopoiesis.Semantic proximity Read ↗

Clonal Hematopoiesis Dynamics and Evolutionary Fitness During Cancer Treatment Impact Clinical OutcomesSemantic proximity Read ↗

Evolution of clonal hematopoiesis during cancer treatment and its impact on outcomes.Semantic proximity Read ↗

Impact of Germline DNA Repair Mutations on Clonal Hematopoiesis and Myeloid Neoplasm Development.Semantic proximity Read ↗

Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid DisordersSemantic proximity Read ↗

Ontogeny and Natural History of Therapy-Related Clonal Hematopoiesis From a Multidisciplinary CHIP Clinic.Semantic proximity Read ↗

Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.Semantic proximity Read ↗

Clonal tumor mutations in homologous recombination genes predict favorable clinical outcome in ovarian cancer treated with platinum-based chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.